Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus [Yahoo! Finance]
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference [Yahoo! Finance]
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
Cocrystal Pharma (NASDAQ:COCP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.